Revenue increased 34.0%
Revenue changed +34.0% from the comparable as-filed period.
$3.4B→$4.6B2 prior comparisons
GROSSPATTERN / DETERMINISTIC EVIDENCE / V3
Search securities →DASH financial changes
Ranked by interpretable importance, issuer history, magnitude, and accounting profile. No directional recommendation.
Operating income increased 71.3%
Operating income changed +71.3% from the comparable as-filed period.
$258.0M→$442.0M2 prior comparisons
Cash & equivalents increased 54.1%
Cash & equivalents changed +54.1% from the comparable as-filed period.
$3.3B→$5.1B2 prior comparisons
Operating margin moved 209 bp higher
Operating margin changed +209 basis points from the comparable as-filed period.
7.49%→9.58%2 prior comparisons
Working capital decreased 44.6%
Working capital changed -44.6% from the comparable as-filed period.
$5.4B→$3.0B3 prior comparisons
Research & development increased 40.6%
Research & development changed +40.6% from the comparable as-filed period.
$355.0M→$499.0M2 prior comparisons
Trade receivables increased 35.6%
Trade receivables changed +35.6% from the comparable as-filed period.
$894.0M→$1.2B3 prior comparisons
Revenue increased 35.6%
Revenue changed +35.6% from the comparable as-filed period.
$3.3B→$4.5B2 prior comparisons
Free-cash-flow proxy increased 101.6%
Free-cash-flow proxy changed +101.6% from the comparable as-filed period.
$438.0M→$883.0M3 prior comparisons
Operating cash flow increased 87.3%
Operating cash flow changed +87.3% from the comparable as-filed period.
$504.0M→$944.0M3 prior comparisons
Working capital decreased 55.1%
Working capital changed -55.1% from the comparable as-filed period.
$5.0B→$2.3B3 prior comparisons
Current liabilities increased 31.0%
Current liabilities changed +31.0% from the comparable as-filed period.
$4.7B→$6.2B3 prior comparisons
Operating margin moved 146 bp lower
Operating margin changed -146 basis points from the comparable as-filed period. This reverses 2 consecutive comparable moves in the opposite direction.
4.96%→3.50%2 prior comparisons
Research & development increased 52.4%
Research & development changed +52.4% from the comparable as-filed period.
$351.0M→$535.0M2 prior comparisons
Trade receivables increased 31.0%
Trade receivables changed +31.0% from the comparable as-filed period.
$840.0M→$1.1B3 prior comparisons
Method Importance combines metric-family relevance, magnitude, issuer-history unusualness, persistence, and financial-statement significance. It is analytical prioritization, not a legal materiality conclusion or investment signal.